Addison Capital Co lessened its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,219 shares of the company’s stock after selling 4,455 shares during the period. Addison Capital Co’s holdings in Teva Pharmaceutical Industries were worth $990,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of TEVA. San Francisco Sentry Investment Group CA bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth $106,000. Bank of Nova Scotia increased its holdings in shares of Teva Pharmaceutical Industries by 8.3% in the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares in the last quarter. Penserra Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $129,000. Americafirst Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth $303,000. Finally, Salem Investment Counselors Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 12.8% in the 2nd quarter. Salem Investment Counselors Inc. now owns 9,400 shares of the company’s stock worth $312,000 after purchasing an additional 1,068 shares in the last quarter. 51.96% of the stock is owned by institutional investors.
TEVA has been the subject of a number of research analyst reports. BTIG Research lifted their target price on Teva Pharmaceutical Industries to $20.00 in a report on Friday, December 15th. ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Evercore ISI set a $38.00 target price on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Wednesday, October 25th. Goldman Sachs Group upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Friday, December 15th. Finally, Citigroup upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Thursday, January 4th. Eight analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $21.32.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, November 2nd. The company reported $0.95 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.03 by ($0.08). Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%. sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd will post 3.72 earnings per share for the current fiscal year.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.